Local Progression or Metastatic Melanoma With Failed First-line Treatment

Oncology
1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

LP
Lee's PharmaceuticalChina - Guangzhou
1 program
1
Pexa-Vec combined with ZKAB001Phase 1/21 trial
Active Trials
NCT04849260Unknown54Est. May 2023

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Lee's PharmaceuticalPexa-Vec combined with ZKAB001

Clinical Trials (1)

Total enrollment: 54 patients across 1 trials

NCT04849260Lee's PharmaceuticalPexa-Vec combined with ZKAB001

Phase Ib/II Clinical Study of Pexa-Vec (Vaccinia GM CSF / Thymidine Kinase-Deactivated Virus) Combined With Recombinant Whole Human Anti-PD-L1 Monoclonal Antibody (ZKAB001) in Metastatic Melanoma

Start: Aug 2021Est. completion: May 202354 patients
Phase 1/2Unknown

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space